Trial
NCT03172026
Maraviroc to Augment Rehabilitation Outcomes After Stroke
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of California, Los Angeles
Collaborators
—
Condition
Stroke
Intervention
Maraviroc 300 mg
Why stopped
Poor recruitment for each site, partly related to Covid epidemic.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-08-03